KMTS
Kestra Medical Technologies, Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.64
P/S
13.83
EV/EBITDA
-6.81
DCF Value
$5.03
FCF Yield
-10.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
48.8%
Operating Margin
-171.5%
Net Margin
-173.0%
ROE
-68.8%
ROA
-38.2%
ROIC
-42.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $24.6M | $-34.2M | $-0.61 |
| Q2 2026 | $22.6M | $-32.8M | $-0.64 |
| Q1 2026 | $19.4M | $-25.8M | $-0.50 |
| Q4 2025 | $17.2M | $-52.1M | $-2.21 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.17
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.